查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988095

抗疟疾药市场：2026-2032年全球市场预测（依药物类别、给药途径、剂型、通路和最终用户划分）

Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗疟疾药市场价值将达到 18.7 亿美元，到 2026 年将成长到 19.9 亿美元，到 2032 年将达到 28.4 亿美元，复合年增长率为 6.12%。

主要市场统计数据
基准年 2025 18.7亿美元
预计年份：2026年 19.9亿美元
预测年份 2032 28.4亿美元
复合年增长率 (%) 6.12%

清晰简洁地介绍了影响抗疟疾药使用和策略决策的现代临床、政策和供应链环境。

疟疾仍然是全球面临的持续性健康挑战，抗疟疾药对于降低疫区人群的发病率和死亡率至关重要。本执行摘要整合了目前影响抗疟治疗的科学、监管和商业性趋势，重点阐述了临床实践、产品可及性和医疗卫生系统准备之间的相互作用。近年来，药物疗效问题、抗药性标记的出现以及治疗指南的不断更新，三者之间呈现出复杂的相互作用，共同影响着临床决策和筹资策略。

不断发展的抗药性科学、更新的治疗策略和供应链韧性如何共同重塑抗疟疾疗法的研发、采购和部署。

抗疟疾药领域正经历着由科学进步、政策转变和市场力量共同驱动的变革。在科学方面，对抗药性机制和分子监测的深入理解正促使治疗指南进行修订，并引发人们对新型联合治疗的浓厚兴趣。同时，诊断技术的改进和综合病例管理方法的进步正在改变需求模式，推动标靶治疗的发展，并减少不合理用药。

贸易政策和关税变化对筹资策略、供应商多元化以及促进抗疟疾药。

美国在2025年实施的关税政策，为国际抗疟疾药供应体系的采购、生产和成本结构带来了新的考量。关税壁垒正在影响采购决策，并可能加速本地化进程，因为买家和製造商需要更具关税优势的供应链和本地化生产。为此，一些製造商正在考虑迁移生产基地或协商长期合同，以将关税的影响内部化，从而保护脆弱市场的价格稳定。

针对治疗分类、给药途径、剂型、通路和最终用户环境等因素进行详细的細項分析，进而形成差异化的需求和策略。

市场区隔分析揭示了对产品开发、分销规划和临床导入策略至关重要的关键细节。从药物类别来看，市场可分为青蒿素类联合治疗和非青蒿素类疗法。前者包括一些特定的组合，例如蒿甲醚/苯芴醇、蒿甲醚/阿莫地喹、蒿甲醚/甲氟喹和青蒿素/哌喹；后者则包括一些传统药物，例如Chloroquine、甲氟喹、伯氨喹和奎宁。了解这些药物类别中的治疗定位和抗药性特征对于药物选择决策和临床指南的发展至关重要。

区域流行病学、监管协调和全球主要地区的生产能力如何影响抗疟疾疗法的取得途径和策略重点。

区域趋势深刻影响着美洲、欧洲、中东和非洲以及亚太地区的医疗资源取得、监管方式和供应链策略，每个地区都具有其独特的流行病学特征和医疗卫生系统能力。在美洲，尤其是在局部疫情爆发和边境地区，重点往往在于采取有针对性的措施、加强监测和维持供应的连续性，与当地製造商的合作以及区域采购机制在确保稳定供应方面发挥着至关重要的作用。

企业策略、伙伴关係和商业实践决定了谁能够在复杂的全球市场中可靠地提供有效的抗疟疾解决方案。

领先企业和机构透过策略性投资、伙伴关係和营运调整，正在塑造抗疟疾治疗的发展方向。创新企业持续投资于新一代化合物和新型给药平台，而成熟的学名药生产商则专注于提高生产效率和优化成本结构，以满足流行地区的持续需求。随着官民合作关係促进后期临床试验、技术转移、生产製造和品质保证等方面的能力建设，合作模式正变得越来越普遍。

为提高抗疟疾药整个价值链的治疗效果、供应链韧性、监管协调和相关人员合作，提出切实可行的策略建议。

产业领导者应采取多管齐下的策略，同时提升临床疗效、增强供应韧性并促进相关人员的合作。首先，增加对抗菌药物抗药性监测、数据共用和适应性临床计画的投入，有助于维持治疗价值并促进政策的及时调整。其次，透过区域製造伙伴关係实现价值链多元化，并加强灌装和包装能力，可以减轻贸易中断和关税的影响，同时提高对区域需求的应对力。

采用透明的混合方法研究途径，结合证据整合、与关键相关人员的访谈以及严格的检验，确保研究结果的可靠性和可操作性。

本执行摘要的研究采用了一种混合方法，将严谨的二手资料整合与有针对性的原始研究相结合，以确保其相关性和有效性。二手资料包括同行评审的临床文献、监管指导文件和公共卫生报告，这些资料均经过严格的评估，以确保调查方法的品质和实际适用性。原始研究包括对临床医生、采购专家、製造企业高管和政策顾问进行结构化访谈，以了解实际观点和实际情况的限制因素。

结论强调，协调的监测、对本地製造的投资以及营运弹性对于维持抗疟疾治疗的有效性至关重要。

总之，目前抗疟疾药的现况受到科学、监管和物流等诸多因素复杂交互作用的影响，需要采取协调一致且以证据为基础的因应措施。抗菌素抗药性监测、适应性政策制定以及对本地生产和供应链系统的定向投资，对于维持疗效和确保公平获取至关重要。相关人员若能将临床知识与从采购设计到现场分发的营运弹性结合，将更有能力应对新出现的挑战，并支持永续的疾病控制工作。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗疟疾药市场：依药物类别划分

  • 青蒿素类联合疗法
    • Artemester Rumefantrine
    • 阿莫地喹
    • 青蒿琥酯甲氟喹
    • 青蒿素哌喹
  • 非青蒿素类疗法
    • Chloroquine
    • 甲氟喹
    • 普里马金
    • 奎宁

第九章：抗疟疾药市场：依给药途径划分

  • 注射药物
  • 口服

第十章：抗疟疾药市场（依剂型划分）

  • 注射药物
  • 悬浮液
  • 药片

第十一章：抗疟疾药市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：抗疟疾药市场：依最终用户划分

  • 门诊部
  • 诊所
  • 医院

第十三章：抗疟疾药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：抗疟疾药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：抗疟疾药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗疟疾药市场

第十七章：中国抗疟疾药市场

第十八章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alkem Laboratories
  • Alliance Pharma
  • Alvizia Health Care
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd.
  • Lincoln Pharmaceuticals
  • Lupin Limited
  • Merck KGaA
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Group
  • Zydus Lifesciences Ltd.
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 1.99 billion in 2026, with a CAGR of 6.12%, reaching USD 2.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 1.99 billion
Forecast Year [2032] USD 2.84 billion
CAGR (%) 6.12%

A clear, concise introduction to the contemporary clinical, policy, and supply chain environment shaping antimalarial drug use and strategic decision-making

Malaria remains a persistent global health challenge, and antimalarial drugs are central to reducing morbidity and mortality in affected populations. This executive summary synthesizes current scientific, regulatory, and commercial dynamics shaping antimalarial therapeutics, emphasizing the intersection of clinical practice, product availability, and health system preparedness. Recent years have witnessed a complex interplay between drug efficacy concerns, emergence of resistance markers, and evolving treatment guidelines, which together influence clinical decision-making and procurement strategies.

Beyond clinical efficacy, the landscape is influenced by manufacturing capacity, supply chain integrity, and policy incentives that determine access in endemic regions. Public-private collaborations and international donor initiatives continue to drive distribution efforts, while national health systems wrestle with integration of new treatment protocols and pharmacovigilance requirements. As a result, stakeholders ranging from clinicians and procurement officers to manufacturers and policymakers must navigate shifting evidence and logistical constraints. This overview provides a concise orientation for decision-makers seeking to understand the contemporary context of antimalarial drugs and to prioritize strategic actions that preserve treatment effectiveness and ensure sustained access.

How evolving resistance science, updated treatment policies, and supply chain resilience are jointly reshaping development, procurement, and deployment of antimalarial therapies

The antimalarial space is undergoing transformative shifts driven by scientific advances, policy change, and market forces. On the scientific front, improved understanding of resistance mechanisms and molecular surveillance has prompted revisions to therapeutic guidance and accelerated interest in novel combination therapies. Concurrently, enhanced diagnostics and integrated case management approaches are altering demand patterns, encouraging targeted treatment and reducing inappropriate drug use.

From a regulatory and policy perspective, rapid updates to national treatment policies have become more common as surveillance data emerges, requiring manufacturers and procurement agencies to be more agile. Commercially, consolidation among generics manufacturers and strategic alliances with research institutions are reshaping supply relationships and capacity planning. Meanwhile, supply chain resilience has risen in priority after recent global disruptions, driving investments in regional manufacturing, buffer stock policies, and diversified sourcing. Taken together, these shifts are redefining how drugs are developed, procured, and deployed, creating both risks and opportunities for stakeholders committed to sustaining effective antimalarial therapy.

Implications of trade policy changes and tariffs on procurement strategies, supplier diversification, and the push toward regional manufacturing for antimalarial supplies

The imposition of tariffs by the United States in 2025 introduced new considerations for procurement, manufacturing, and cost structures within the international antimalarial supply ecosystem. Tariff barriers influence sourcing decisions and may accelerate regionalization efforts as purchasers and manufacturers seek tariff-efficient supply chains and localized production. In response, some manufacturers have evaluated shifting production footprints or negotiating long-term contracts that internalize tariff impacts to protect price stability in vulnerable markets.

Healthcare purchasers and national programs have needed to reassess tender specifications and supplier diversification to mitigate potential disruptions. Moreover, tariff-related changes have reinforced the strategic importance of regional manufacturing hubs and in-country fill-and-finish capabilities, which can reduce exposure to international trade frictions. At the same time, donor agencies and multilateral partners have had to adapt funding models to accommodate altered cost dynamics, prioritizing interventions that preserve access while promoting sustainable local capacity. Overall, tariffs have catalyzed a reevaluation of supply chain strategies and underscored the advantage of flexible procurement approaches that can absorb policy-driven shocks.

Detailed segmentation insights highlighting therapeutic classes, administration routes, formulations, distribution channels, and end-user settings that drive differentiated demand and strategy

Segmentation analysis reveals critical nuances that should inform product development, distribution planning, and clinical adoption strategies. When considering drug class, the market is partitioned between artemisinin-based combination therapies and non-artemisinin therapies, with the former encompassing specific combinations such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine, and the latter including classic agents like chloroquine, mefloquine, primaquine, and quinine; understanding therapeutic niches and resistance profiles across those classes is essential for formulary decisions and clinical guidelines.

Route of administration is another differentiator, with oral and injectable modalities presenting distinct use cases: oral formulations are central to outpatient management and mass drug administration campaigns, whereas injectables are critical for severe malaria and inpatient care. Formulation considerations-whether injectables, suspensions, or tablets-affect manufacturing complexity, cold chain needs, and adherence outcomes. Distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, create divergent pathways to end users and require tailored commercial and regulatory approaches. Finally, end user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand concentrates, how treatment protocols vary by setting, and where investments in training and supply chain interventions will have the greatest impact.

How regional epidemiology, regulatory harmonization, and manufacturing capacity across major global regions shape access pathways and strategic priorities for antimalarial therapies

Regional dynamics deeply influence access, regulatory approaches, and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct epidemiological profiles and health system capacities. In the Americas, the focus often lies on targeted control measures, surveillance strengthening, and maintaining supply continuity for localized outbreaks and border areas; partnership with local manufacturers and regional procurement mechanisms plays a role in ensuring steady availability.

In Europe, the Middle East & Africa, regulatory harmonization efforts and donor-supported programs intersect with high-burden settings in parts of Africa, where access and resistance management remain priorities; investments in surveillance infrastructure and capacity building are particularly impactful. Across Asia-Pacific, complex epidemiology and pockets of multidrug resistance have driven innovation in treatment protocols and accelerated adoption of combination therapies, while robust generic manufacturing in parts of the region affects global supply flows. Collectively, these regional patterns necessitate differentiated strategies for policy engagement, procurement design, and local capacity strengthening to match clinical needs and health system realities.

Corporate strategies, partnerships, and operational practices that are determining who can reliably deliver effective antimalarial solutions in complex global markets

Key corporate and institutional behaviors are shaping the trajectory of antimalarial therapeutics through strategic investments, partnerships, and operational adjustments. Innovator companies continue to invest in next-generation compounds and novel delivery platforms, while established generic manufacturers focus on scaling production efficiency and improving cost structures to meet sustained demand in endemic markets. Collaborative models are increasingly common, with public-private partnerships facilitating late-stage clinical studies, technology transfer, and capacity building in manufacturing and quality assurance.

At the same time, contract manufacturers and specialty formulation providers play a vital role in enabling rapid scale-up and in-country fill-and-finish operations. Strategic alliances between pharmaceutical firms and diagnostic developers are also emerging to align treatment with improved case detection. From a commercial perspective, companies that combine robust pharmacovigilance, compliance with international quality standards, and responsive supply chain capabilities are best positioned to support national programs and international donors. Overall, the market rewards organizations that balance R&D innovation with reliable manufacturing and deep operational understanding of endemic markets.

Actionable strategic recommendations for strengthening therapeutic efficacy, supply chain resilience, regulatory alignment, and stakeholder collaboration across the antimalarial value chain

Industry leaders should adopt a multi-pronged strategy that concurrently advances clinical efficacy, supply resilience, and stakeholder collaboration. First, investment in resistance surveillance, data sharing, and adaptive clinical programs will preserve therapeutic value and inform timely policy adaptations. Second, diversifying supply chains through regional manufacturing partnerships and strengthened fill-and-finish capabilities will reduce exposure to trade disruptions and tariffs while improving responsiveness to localized demand.

Beyond procurement and manufacturing, organizations should prioritize integrated product stewardship, coupling reliable pharmacovigilance with provider education to sustain appropriate use. Engaging proactively with regulatory bodies and multilateral donors enables alignment of procurement frameworks with public health goals. Finally, adopting digital tools for demand forecasting, inventory visibility, and quality monitoring enhances decision-making across the product lifecycle. Taken together, these actions create a resilient approach that supports effective treatment delivery and long-term viability of antimalarial interventions.

A transparent mixed-methods research approach combining evidence synthesis, primary stakeholder interviews, and rigorous validation to ensure credible insights and practical relevance

The research underpinning this executive summary deployed a mixed-methods approach combining rigorous secondary evidence synthesis with targeted primary inquiry to ensure validity and relevance. Secondary inputs included peer-reviewed clinical literature, regulatory guidance documents, and public health reports that were critically appraised for methodological quality and applicability to practice. Primary research involved structured interviews with clinicians, procurement specialists, manufacturing executives, and policy advisors to capture operational perspectives and real-world constraints.

Data triangulation and cross-validation techniques were applied to reconcile divergent sources and to identify consistent patterns. Attention was paid to temporal factors and recent policy changes to ensure the analysis reflects the most current realities. Where quantitative data were limited, qualitative insights were used to contextualize trends and infer strategic implications. Finally, quality assurance measures, including expert peer review and methodological transparency, were implemented to enhance credibility and to provide stakeholders with confidence in the report's findings and recommendations.

Concluding insights emphasizing the imperative of coordinated surveillance, regional manufacturing investments, and operational agility to sustain antimalarial treatment effectiveness

In conclusion, the antimalarial drugs landscape is defined by a confluence of scientific, regulatory, and logistical dynamics that require coordinated, evidence-driven responses. Resistance surveillance, adaptive policy-making, and targeted investments in regional manufacturing and supply chain systems are central to preserving treatment effectiveness and ensuring equitable access. Stakeholders who integrate clinical intelligence with operational agility - from procurement design to on-the-ground distribution - will be better positioned to respond to emerging challenges and to support sustainable disease control efforts.

Moving forward, the emphasis should remain on collaboration across public, private, and philanthropic actors to align incentives, share data, and build capacity where it matters most. By focusing on resilient supply chains, responsive regulatory engagement, and stewardship of existing therapeutics while fostering innovation, the global community can sustain progress against malaria and protect vulnerable populations from preventable illness and death.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimalarial Drugs Market, by Drug Class

  • 8.1. Artemisinin Based Combination Therapy
    • 8.1.1. Artemether Lumefantrine
    • 8.1.2. Artesunate Amodiaquine
    • 8.1.3. Artesunate Mefloquine
    • 8.1.4. Dihydroartemisinin Piperaquine
  • 8.2. Non Artemisinin Therapies
    • 8.2.1. Chloroquine
    • 8.2.2. Mefloquine
    • 8.2.3. Primaquine
    • 8.2.4. Quinine

9. Antimalarial Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Antimalarial Drugs Market, by Formulation

  • 10.1. Injectables
  • 10.2. Suspensions
  • 10.3. Tablets

11. Antimalarial Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Antimalarial Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Antimalarial Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimalarial Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimalarial Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antimalarial Drugs Market

17. China Antimalarial Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alkem Laboratories
  • 18.7. Alliance Pharma
  • 18.8. Alvizia Health Care
  • 18.9. Bayer AG
  • 18.10. Cipla Inc.
  • 18.11. Dr. Reddy's Laboratories
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. GlaxoSmithKline plc
  • 18.14. Glenmark Pharmaceuticals
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Ipca Laboratories Ltd.
  • 18.17. Lincoln Pharmaceuticals
  • 18.18. Lupin Limited
  • 18.19. Merck KGaA
  • 18.20. Mylan
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Sanofi Group
  • 18.24. Strides Pharma Science Limited
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Takeda Pharmaceutical Company
  • 18.27. Teva Pharmaceuticals Industries Ltd.
  • 18.28. Zydus Group
  • 18.29. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)